United Kingdom (UK)
Recombinant monoclonal antibody to PAI-1. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 8H9D4.
UniProt Accession Number of Target Protein: P05121
Alternative Name(s) of Target: SERPINE1; PAI1; PAI; PLANH1; Plasminogen activator inhibitor 1; Endothelial plasminogen activator inhibitor; Serpin E1; MA-8H9D4; APG
Immunogen: The original antibody was generated using PAI-1 complex as an immunogen.
Specificity: This antibody binds human PAI-1 at an epitope between amino acids 277 and 327, more particularly it binds residues between Arg300, Gln303 and Asp305 located on the loop between α-helix I and β-strand 5A. This antibody cross-reacts with pig PAI-1 but not with mouse or rat. Plasminogen activator inhibitor-1 (PAI-1), is a serine protease inhibitor, a unique member of the serpin superfamily which plays an important role in fibrinolysis and is an established risk factor for cardiovascular diseases. It a primary inhibitor of tissue-type plasminogen activator (PLAT) and urokinase-type plasminogen activator (PLAU). As PLAT inhibitor, it is required for fibrinolysis down-regulation and is responsible for the controlled degradation of blood clots. As PLAU inhibitor, it is involved in the regulation of cell adhesion and spreading .
Application Notes: This antibody is reported to have strong inhibitory effect towards PAI-1 activity. The cross reactivity of this antibody towards other PAI-1 than human was done using ELISA (PMID: 9048903). This antibody shifts the reaction to the substrate pathway without decreasing the rate-limiting constant for reactive center loop insertion by tPA (PMID: 12223472). This antibody interferes with the final locking step in the serpin/proteinase interaction, thereby explaining its substrate inducing properties (PMID: 12871373).
Antibody first published in:
Debrock et al. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms. Biochim Biophys Acta. 1997 Feb 8;1337(2):257-66. PMID:9048903
Note on publication:
The paper investigates two mechanisms of neutralization of the inhibitory activity of PAI-1 using monoclonal antibodies.